The systematic study of Specialized pro-resolving mediators (SPMs)—lipid-derived molecules that actively terminate inflammation and orchestrate tissue repair. Unlike simple anti-inflammatory suppression, resoleomics examines how omega-3 fatty acids and omega-6 substrates are enzymatically converted into Resolvins, Protectins, Maresins, and Lipoxins that signal "inflammation complete" and transition tissue from defensive destruction to active healing.
Think of inflammation like a war in your tissues. Most anti-inflammatory drugs are like a ceasefire imposed from outside—they stop the fighting, but they leave bodies on the battlefield, unrepaired barricades, and exhausted soldiers still standing guard. Resoleomics is the peace process—the specialized diplomats (SPMs) who arrive after the battle to actively clear the dead, repair the damage, and send soldiers home. These diplomats have specific passports (ALX/FPR2 receptor, ERV1/ChemR23, DRV1/GPR32) that let them into cells to give new orders: "Stop recruiting reinforcements. Clean up the debris. Start rebuilding." Without enough diplomatic materials (DHA, EPA), the war drags on—chronic inflammation, the tissue equivalent of forever troops. When you pop an NSAID or ice an injury immediately, you're not just stopping the fight—you're blocking the factory that makes the diplomats. The war ends, but no one cleans up or rebuilds properly. This is why some injuries never quite heal right.
Resoleomics begins with essential fatty acid conversion via three enzymatic pathways:
DHA Pathway (D-series SPMs):
DHA → 15-LOX → 17S-hydroxy-DHA → Resolvin D-series (RvD1-6), Protectins (PD1/NPD1), Maresins (MaR1, MaR2)
EPA Pathway (E-series SPMs):
EPA → 5-LOX → 18R-hydroxy-EPA → Resolvin E-series (RvE1-3)
Aspirin-Acetylated Pathway:
Aspirin acetylates COX-2 → COX-2 acetylation converts DHA/EPA → 15-epi-lipoxins and aspirin-triggered resolvins (AT-RvD1, AT-RvD3)
SPM Receptor Signaling:
- RvD1/RvD2 → ALX/FPR2 + DRV1/GPR32 → inhibit NF-kB, activate SOCS1 and SOCS3
- RvE1 → ERV1/ChemR23 + reduce LTB4 production
- MaR1 → activate macrophage Efferocytosis via PPARα
- PD1/NPD1 → block TNF-α and NF-κB signaling
Downstream Effects:
SPM receptor activation → stop neutrophil transmigration (block L-selectin shedding) → enhance macrophage phagocytosis of apoptotic cells → polarize M2 macrophages → reduce IL-1β, IL-6, TNF-α → increase IL-10, TGF-beta → promote collagen deposition and wound healing
graph TD
A[DHA/EPA substrates] --> B[15-LOX/5-LOX enzymes]
B --> C[Intermediate hydroxy-fatty acids]
C --> D{SPM Class Switch}
D --> E[Resolvins]
D --> F[Protectins]
D --> G[Maresins]
E --> H[ALX/FPR2 receptors]
F --> I[GPR37 receptors]
G --> J[Macrophage activation]
H --> K[Stop neutrophil recruitment]
H --> L["↓ NF-κB signaling"]
I --> M[Neuroprotection]
J --> N[Efferocytosis]
K --> O[Resolution Phase]
L --> O
M --> O
N --> O
O --> P[Tissue repair & homeostasis]
Q[NSAIDs block COX-2] -.blocks.-> D
R["Ice therapy ↓ enzyme activity"] -.impairs.-> B
S[Omega-3 deficiency] -.starves.-> A
Resoleomics explains why inflammation becomes chronic in modern disease—it's not excessive inflammation starting, it's failed resolution. This maps directly to:
Metamodel 5 (Evolutionary Mismatch): Hunter-gatherers consumed omega-6:omega-3 ratios of 1:1 to 4:1; modern diets reach 20:1, starving SPM production. The Eicosanoid Class Switch from pro-inflammatory LTB4 to pro-resolving RvD1 cannot occur without substrate.
Selfish Immune System: In chronic inflammation, the immune system continues extracting resources (energy, amino acids) for defensive operations because it never receives the "stand down" signal SPMs provide. This creates metabolic exhaustion and sarcopenia.
Clinical Thresholds:
- Omega-3 index <4% predicts poor SPM synthesis capacity
- RvD1 levels <50 pg/mL correlate with delayed wound healing
- LTB4:RvE1 ratio >100:1 indicates resolution failure
Intervention Implications:
- Omega-3 supplementation: EPA/DHA 2-4g daily (triglyceride form, taken with fat)
- Avoid NSAID overuse: Particularly in first 48-72h post-injury when COX-2 is synthesizing aspirin-triggered resolvins
- Reconsider ice protocols: Prolonged icing (>20 min, multiple times daily) may impair enzymatic SPM synthesis by reducing tissue temperature below optimal enzyme function
- Support 15-LOX activity: Adequate B12, selenium, vitamin E as cofactors
- Low-dose aspirin timing: 81mg aspirin acetylates COX-2 without blocking it, enhancing AT-resolvin production
Clinical Applications:
- SPMs are not simply anti-inflammatory—they are actively pro-resolving, meaning they give specific "clean up and repair" signals
- The Eicosanoid Class Switch typically occurs 6-24 hours post-injury as COX-2 and lipoxygenases shift from making prostaglandins to making SPMs
- NSAID block COX-2 indiscriminately, preventing both prostaglandin AND aspirin-triggered lipoxin/resolvin production
- Ice therapy may impair resolution: enzymatic activity of 15-LOX drops 40-60% at temperatures <32°C
- Neutrophil recruitment stops when RvD1 binds ALX/FPR2 receptor and blocks L-selectin shedding (preventing neutrophil rolling adhesion)
- Efferocytosis (macrophage clearance of apoptotic cells) increases 3-5 fold in presence of MaR1 and RvD2
- Omega-3 deficiency (<4% erythrocyte membrane omega-3 index) correlates with 60-80% reduction in SPM production capacity
- The half-life of SPMs is brief (minutes to hours), requiring continuous synthesis from dietary precursors
- RvD1 at 100 ng/kg body weight reduces neutrophil infiltration by 50% in experimental peritonitis
- Aspirin-triggered resolvins (15-epi-LXA4, AT-RvD1) are 3-10x more potent than their non-acetylated forms
- SPM levels decline with age, contributing to inflammaging—chronic low-grade inflammation in elderly
- Obese adipose tissue shows 70% lower SPM levels despite higher baseline inflammation, creating a resolution deficit
- Specialized pro-resolving mediators (SPMs) — the molecular family studied in resoleomics
- Eicosanoid Class Switch — the temporal shift from pro-inflammatory to pro-resolving lipid mediators
- Resolvins — major SPM class (D-series from DHA, E-series from EPA)
- Protectins — DHA-derived SPMs with neuroprotective effects
- Maresins — macrophage-generated SPMs promoting efferocytosis
- Lipoxins — arachidonic acid-derived pro-resolving mediators, first discovered SPM class
- omega-3 fatty acids — essential dietary substrate for resoleomics
- DHA — precursor for D-series resolvins, protectins, and maresins
- EPA — precursor for E-series resolvins
- 15-LOX — key enzyme converting DHA to resolvins and protectins
- 5-LOX — enzyme producing leukotriene B4 (pro-inflammatory) and resolvin E-series (pro-resolving)
- COX-2 — produces prostaglandins acutely, then SPMs during resolution phase
- COX-2 acetylation — aspirin modification that produces aspirin-triggered resolvins
- Aspirin-triggered resolvins — more potent SPMs formed via acetylated COX-2
- ALX/FPR2 receptor — G-protein coupled receptor binding RvD1, lipoxins, and annexin A1
- Efferocytosis — macrophage clearance of apoptotic cells, enhanced 3-5 fold by maresins
- NSAIDs — block COX-2, impairing both prostaglandin and SPM synthesis
- chronic inflammation — results from failed resolution when SPM production is inadequate
- M2 macrophages — anti-inflammatory macrophage phenotype promoted by SPMs
- neutrophils — recruitment halted by resolvins binding ALX/FPR2
- wound healing — requires successful SPM-mediated resolution to progress from inflammation to repair
- IL-6 — reduced by SPM signaling through SOCS pathway activation
- TNF-α — pro-inflammatory cytokine suppressed by resolvin and protectin signaling
- NF-kB — transcription factor inhibited by SPM receptor activation
- SOCS1 — suppressor of cytokine signaling upregulated by resolvins
- PPARα — nuclear receptor activated by maresins to promote lipid metabolism and resolution
- Arachidonic acid — omega-6 fatty acid precursor to lipoxins (pro-resolving) and leukotrienes (pro-inflammatory)
- LTB4 — potent neutrophil chemoattractant whose levels must decrease for resolution
- Metabolic flexibility — impaired when chronic inflammation drains resources due to failed resolution
- Brain-derived neurotrophic factor — increased by neuroprotectin D1 in brain
- Inflammaging — age-related decline in SPM production contributes to chronic low-grade inflammation
- Module 1 — Resoleomics introduced as the lipid mediator resolution pathway
- Module 4 — SPMs in context of chronic disease and failed resolution
- Module 5 — Evolutionary mismatch in omega-3 availability and modern resolution failure